Trends in capacity utilization for therapeutic monoclonal antibody production.
The administration of high doses of therapeutic antibodies requires large-scale, efficient, cost effective manufacturing processes. An understanding of how the industry is using its available production capacity is important for production planning, and facility expansion analysis. Inaccurate production planning for therapeutic antibodies can have serious financial ramifications. In the recent 5(th) Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production, 434 qualified respondents from 39 countries were asked to indicate, among other manufacturing issues, their current trends and future predictions with respect to the production capacity utilization of monoclonal antibodies in mammalian cell culture systems. While overall production of monoclonals has expanded dramatically since 2003, the average capacity utilization for mammalian cell culture systems, has decreased each year since 2003. Biomanufacturers aggressively attempt to avoid unanticipated high production demands that can create a capacity crunch. We summarize trends associated with capacity utilization and capacity constraints which indicate that biopharmaceutical manufacturers are doing a better job planning for capacity. The results have been a smoothing of capacity use shifts and an improved ability to forecast capacity and outsourcing needs. Despite these data, today, the instability and financial constraints caused by the current global economic crisis are likely to create unforeseen shifts in our capacity utilization and capacity expansion trends. These shifts will need to be measured in subsequent studies.
Langer
Eric S
ES
BioPlan Associates, Inc, Rockville, MD, USA. elanger@bioplanassociates.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000191:economics / Q000627:therapeutic use*; D001702:Biopharmaceutics / Q000191:economics / Q000379:methods / Q000639:trends*; D019149:Bioreactors; D001709:Biotechnology / Q000191:economics / Q000379:methods / Q000458:organization & administration / Q000639:trends*; D018929:Cell Culture Techniques; D004345:Drug Industry / Q000191:economics / Q000379:methods / Q000458:organization & administration / Q000639:trends*; D005060:Europe; D006801:Humans; D014481:United States
D000911:Antibodies, Monoclonal